Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.

ABSTRACT: Metastatic breast cancer remains an incurable disease, and new therapies are needed. One major limitation of chemotherapy is the toxicity associated with higher dose exposure. Antibody-drug conjugates (ADCs) are a complex and evolving class of agents specifically designed with the objective of delivering antineoplastic medicines in the most precise and selectively targeted way. ADCs are composed of four key components: (1) the target antigen, (2) an antibody construct, (3) a payload (most commonly a cytotoxic agent), and (4) a linker moiety that couples the payload and the antibody. In this review, we discuss the clinical development of ADCs for the treatment of breast cancer, focusing on two recently FDA-approved agents, trastuzumab deruxtecan and sacituzumab govitecan, and discuss the on

SUBMITTER: Barroso-Sousa R 

PROVIDER: S-EPMC7933915 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature